Indication and Usage

SOLODYN is indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.

SOLODYN did not demonstrate any effect on non-inflammatory acne lesions. Safety of SOLODYN has not been established beyond 12 weeks of use. This formulation of minocycline has not been evaluated in the treatment of infections. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, SOLODYN should be used only as indicated.

Important Safety Information

To report SUSPECTED ADVERSE REACTIONS, contact Valeant Pharmaceuticals North America LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or visit

Reference: 1. SOLODYN Tablets Package Insert. Valeant Pharmaceuticals North America LLC.

Solodyn is a trademark of Valeant Pharmaceuticals International, Inc. or its affiliates.
© 2017 Valeant Pharmaceuticals North America LLC. SDN.0021.USA.17